RPRX
Royalty Pharma plc NASDAQ Listed Jun 16, 2020$52.96
After hrs
$52.95
-0.02%
Mkt Cap $22.8B
52w Low $34.08
84.2% of range
52w High $56.50
50d MA $51.91
200d MA $43.26
P/E (TTM)
29.8x
EV/EBITDA
23.2x
P/B
2.4x
Debt/Equity
1.4x
ROE
20.4%
P/FCF
11.9x
RSI (14)
35.40
ATR (14)
$1.41
Beta
0.39
50d MA
$51.91
200d MA
$43.26
Avg Volume
4.1M
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
110 East 59th Street · New York City, NY 10022 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 11, 2026 | BMO | 1.29 | 1.46 | +13.2% | 44.25 | -0.0% | +1.2% | +0.9% | +0.5% | -0.2% | -0.5% | — |
| Nov 5, 2025 | BMO | 0.99 | 1.17 | +17.7% | 40.42 | +0.6% | +0.9% | -5.4% | -0.1% | +1.1% | +1.6% | — |
| Aug 6, 2025 | BMO | 1.03 | 1.14 | +10.7% | 37.12 | +0.0% | -0.3% | +1.5% | -3.7% | -0.9% | +1.7% | — |
| May 8, 2025 | BMO | 0.95 | 1.06 | +11.2% | 33.10 | +0.4% | +0.2% | +0.6% | -1.6% | -1.6% | +2.6% | — |
| Feb 11, 2025 | BMO | 0.99 | 1.15 | +16.2% | 32.25 | +0.1% | +0.3% | +0.4% | -0.3% | +1.5% | -0.8% | — |
| Nov 6, 2024 | BMO | 0.93 | 1.04 | +12.1% | 26.64 | +1.4% | -0.5% | -1.2% | +0.6% | -1.4% | -0.6% | — |
| Aug 8, 2024 | BMO | 0.96 | 0.96 | -0.5% | 26.15 | +0.7% | +0.4% | +0.7% | +1.6% | -0.8% | +2.9% | — |
| May 9, 2024 | BMO | 0.99 | 0.98 | -0.7% | 27.97 | +1.9% | +0.4% | +1.0% | -1.1% | +0.5% | -1.2% | — |
| Feb 15, 2024 | BMO | 1.01 | 1.15 | +13.9% | 30.03 | +0.0% | -0.4% | +1.3% | +3.1% | -0.7% | +0.0% | — |
| Nov 8, 2023 | BMO | 0.81 | 0.79 | -2.5% | 27.62 | +0.9% | -0.8% | -0.7% | -0.4% | +1.5% | -1.8% | — |
| Aug 8, 2023 | BMO | 0.83 | 0.85 | +2.4% | 30.55 | +0.6% | +0.0% | +0.1% | -0.3% | -1.2% | -1.0% | — |
| May 9, 2023 | BMO | 1.32 | 1.60 | +21.2% | 33.99 | -0.1% | -0.4% | +1.9% | +0.1% | -0.6% | -3.2% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 21 | UBS | Maintains | Buy → Buy | — | $49.30 | $49.59 | +0.6% | +0.4% | +0.5% | -0.2% | -0.5% | +0.5% |
| Apr 10 | Morgan Stanley | Maintains | Overweight → Overweight | — | $48.30 | $48.30 | +0.0% | -0.8% | +1.1% | +0.8% | -0.2% | -0.5% |
| Jan 30 | UBS | Upgrade | Neutral → Buy | — | $40.86 | $41.27 | +1.0% | +2.0% | +1.6% | +1.4% | +1.7% | +1.0% |
| Jan 27 | Citigroup | Maintains | Buy → Buy | — | $40.47 | $40.50 | +0.1% | +0.7% | -0.8% | +1.1% | +2.0% | +1.6% |
| Dec 11 | TD Cowen | Maintains | Buy → Buy | — | $38.26 | $38.30 | +0.1% | +1.4% | -1.1% | +0.4% | -0.4% | -0.2% |
| Oct 10 | Morgan Stanley | Maintains | Overweight → Overweight | — | $36.14 | $36.32 | +0.5% | -0.4% | -1.6% | +1.6% | +0.5% | +0.4% |
| Jul 22 | Citigroup | Maintains | Buy → Buy | — | $35.65 | $35.65 | +0.0% | +1.3% | -0.2% | +1.6% | +0.2% | +1.1% |
| Jul 10 | Morgan Stanley | Maintains | Overweight → Overweight | — | $35.87 | $36.00 | +0.4% | +0.7% | -0.8% | +1.1% | +0.7% | -2.5% |
| Oct 25 | Citigroup | Maintains | Buy → Buy | — | $27.28 | $27.35 | +0.3% | -1.2% | +1.2% | -0.4% | +0.1% | -0.7% |
| Aug 14 | Goldman Sachs | Maintains | Buy → Buy | — | $26.86 | $26.81 | -0.2% | -0.8% | +2.9% | -0.9% | +1.2% | -0.8% |
| Jul 11 | Morgan Stanley | Maintains | Overweight → Overweight | — | $25.73 | $25.96 | +0.9% | +3.9% | +0.1% | -0.4% | +3.9% | +1.5% |
| Jun 3 | UBS | Downgrade | Buy → Neutral | — | $27.41 | $27.10 | -1.1% | -2.1% | +0.7% | -0.1% | +0.3% | +1.4% |
| Apr 12 | BofA Securities | Maintains | Buy → Buy | — | $29.05 | $29.06 | +0.0% | -2.9% | +0.1% | -2.8% | +0.5% | +1.0% |
| Feb 20 | Goldman Sachs | Maintains | Buy → Buy | — | $29.92 | $29.91 | -0.0% | +1.3% | +3.1% | -0.7% | +0.0% | +1.0% |
| Feb 20 | JP Morgan | Maintains | Overweight → Overweight | — | $29.92 | $29.91 | -0.0% | +1.3% | +3.1% | -0.7% | +0.0% | +1.0% |
| Nov 9 | Morgan Stanley | Maintains | Overweight → Overweight | — | $27.62 | $27.87 | +0.9% | -0.8% | -0.7% | -0.4% | +1.5% | -1.8% |
| Oct 11 | Morgan Stanley | Maintains | Overweight → Overweight | — | $26.93 | $26.95 | +0.1% | +0.8% | -0.1% | +2.7% | +0.4% | +1.9% |
| Aug 9 | Morgan Stanley | Maintains | Overweight → Overweight | — | $30.55 | $30.72 | +0.6% | +0.0% | +0.1% | -0.3% | -1.2% | -1.0% |
| Jul 11 | Morgan Stanley | Maintains | Overweight → Overweight | — | $30.05 | $30.26 | +0.7% | +2.2% | +1.9% | -1.8% | +0.1% | -0.3% |
| May 10 | Morgan Stanley | Maintains | Overweight → Overweight | — | $33.99 | $33.96 | -0.1% | -0.4% | +1.9% | +0.1% | -0.6% | -3.2% |
| Apr 10 | Morgan Stanley | Maintains | Overweight → Overweight | — | $36.38 | $36.58 | +0.5% | -0.2% | +0.6% | -1.1% | +1.2% | -0.7% |
| Apr 6 | Tigress Financial | Maintains | Buy → Buy | — | $36.27 | $36.43 | +0.4% | +0.3% | -0.2% | +0.6% | -1.1% | +1.2% |
| Feb 16 | UBS | Maintains | Buy → Buy | — | $37.69 | $37.53 | -0.4% | -1.2% | +1.6% | -1.5% | -0.4% | +0.0% |
| Dec 6 | Morgan Stanley | Maintains | Overweight → Overweight | — | $43.01 | $42.85 | -0.4% | -2.5% | +0.5% | +0.5% | -1.4% | +1.0% |
| Nov 9 | Morgan Stanley | Maintains | Overweight → Overweight | — | $42.69 | $42.82 | +0.3% | +0.8% | +2.2% | -0.2% | -3.2% | -1.0% |
| Oct 18 | JP Morgan | Maintains | Overweight → Overweight | — | $41.78 | $42.21 | +1.0% | +0.6% | -2.3% | -0.4% | +0.4% | +0.6% |
| Sep 13 | Scotiabank | Maintains | Outperform → Outperform | — | $43.64 | $43.04 | -1.4% | -2.4% | -0.4% | -0.6% | -0.5% | -0.7% |
| Aug 8 | Morgan Stanley | Maintains | Overweight → Overweight | — | $42.45 | $42.60 | +0.4% | +1.6% | +1.3% | +0.6% | -0.5% | +1.1% |
| Jul 14 | Tigress Financial | Maintains | Buy → Buy | — | $42.39 | $42.33 | -0.1% | +1.9% | +1.7% | -0.5% | -0.1% | -1.5% |
| Jun 14 | UBS | Maintains | Buy → Buy | — | $38.46 | $38.34 | -0.3% | -0.7% | +0.9% | -0.5% | +2.7% | +1.9% |
| May 13 | Scotiabank | Maintains | Outperform → Outperform | — | $38.95 | $40.00 | +2.7% | +2.5% | +0.8% | +2.7% | -2.1% | -1.8% |
| Apr 27 | Goldman Sachs | Maintains | Buy → Buy | — | $41.83 | $42.19 | +0.9% | +2.8% | +1.3% | -2.2% | -0.5% | +0.8% |
| Apr 14 | JP Morgan | Upgrade | Neutral → Overweight | — | $42.44 | $43.18 | +1.7% | +3.9% | +0.0% | +0.2% | +0.0% | -1.4% |
| Apr 6 | Morgan Stanley | Upgrade | Equal Weight → Overweight | — | $39.84 | $39.92 | +0.2% | +1.4% | +1.1% | +1.4% | +0.2% | +0.7% |
| Oct 29 | Citigroup | Upgrade | Neutral → Buy | — | $38.20 | $39.10 | +2.4% | +3.5% | +0.5% | -4.1% | +3.6% | +0.2% |
| Aug 16 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $38.73 | $38.67 | -0.2% | -1.2% | +2.2% | -0.9% | +0.4% | +0.3% |
| Jul 30 | Tigress Financial | Maintains | Buy → Buy | — | $38.25 | $38.32 | +0.2% | -0.1% | -2.6% | +1.3% | -2.5% | +1.4% |
| Nov 9 | UBS | Upgrade | Neutral → Buy | — | $40.24 | $42.86 | +6.5% | +1.8% | -0.9% | -0.7% | +0.8% | +3.6% |
| Jul 13 | BofA Securities | Maintains | Buy → Buy | — | $47.64 | $47.20 | -0.9% | -7.5% | -1.2% | -1.2% | -1.9% | +4.7% |
| Jul 13 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $47.64 | $47.20 | -0.9% | -7.5% | -1.2% | -1.2% | -1.9% | +4.7% |
| Jul 13 | TD Cowen | Maintains | Outperform → Outperform | — | $47.64 | $47.20 | -0.9% | -7.5% | -1.2% | -1.2% | -1.9% | +4.7% |
| Jul 13 | SunTrust Robinson Humphrey | Maintains | Buy → Buy | — | $47.64 | $47.20 | -0.9% | -7.5% | -1.2% | -1.2% | -1.9% | +4.7% |
| Jul 13 | JP Morgan | Maintains | Neutral → Neutral | — | $47.64 | $47.20 | -0.9% | -7.5% | -1.2% | -1.2% | -1.9% | +4.7% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 26, 2026 | Coyne Terrance P.Off | EVP & CFO | Sell | 64,399 | $53.98 | $3.5M | — | +2.35% | +0.09% |
| Apr 28, 2026 | Coyne Terrance P.Off | EVP & CFO | Sell | 1,875 | $49.78 | $93K | 40,136 | -1.24% | -1.03% |
| Apr 28, 2026 | Coyne Terrance P.Off | EVP & CFO | Sell | 32,916 | $49.78 | $1.6M | — | -1.24% | -1.03% |
8-K · 2.02
!! High
Royalty Pharma plc -- 8-K 2.02: Earnings Results
Royalty Pharma reported Q1 2026 earnings on May 6, 2026, with results available in the accompanying press release for investor review and analysis.
May 6
8-K
Unknown — 8-K Filing
Revolution Medicines secured up to $1 billion in non-dilutive financing tied to daraxonrasib's FDA approval milestones, reducing capital needs while Royalty Pharma gains royalty upside if the drug achieves blockbuster sales.
Apr 13
8-K
Royalty Pharma plc Class A -- 8-K Filing
Royalty Pharma delivered strong 2025 performance with 16% portfolio receipt growth, record shareholder returns, and $2.6 billion in new royalty investments, demonstrating robust cash generation and strategic capital deployment.
Feb 11
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Morgan Stanley | 110,548,138 | $4.3B | Added | Dec 2025 |
| 2 | Fmr Llc | 25,152,242 | $1.2B | Reduced | Mar 2026 |
| 3 | Swedbank Ab | 11,586,693 | $556M | Reduced | Mar 2026 |
| 4 | Capital World Investors | 8,036,714 | $386M | New | Mar 2026 |
| 5 | Caledonia (Private) Investments Pty Ltd | 7,168,399 | $344M | Reduced | Mar 2026 |
| 6 | Vanguard Capital Management Llc | 4,531,886 | $217M | New | Mar 2026 |
| 7 | Jane Street Group, Llc | 4,947,409 | $191M | Added | Dec 2025 |
| 8 | Victory Capital Management Inc | 3,853,808 | $185M | Reduced | Mar 2026 |
| 9 | Northern Trust Corp | 3,808,735 | $183M | Reduced | Mar 2026 |
| 10 | Royal London Asset Management Ltd | 3,808,353 | $183M | Added | Mar 2026 |
| 11 | Invesco Ltd. | 3,752,399 | $180M | Added | Mar 2026 |
| 12 | Aqr Capital Management Llc | 3,782,038 | $180M | Added | Mar 2026 |
| 13 | Patient Capital Management, Llc | 3,643,716 | $175M | Added | Mar 2026 |
| 14 | Bank Of America Corp /de/ | 3,495,846 | $168M | Added | Mar 2026 |
| 15 | Amundi | 3,088,773 | $148M | New | Mar 2026 |
| 16 | Citadel Advisors Llc | 2,681,069 | $129M | Reduced | Mar 2026 |
| 17 | New South Capital Management Inc | 2,625,863 | $126M | Reduced | Mar 2026 |
| 18 | Dorsey Asset Management | 2,276,570 | $109M | Added | Mar 2026 |
| 19 | Vanguard Portfolio Management Llc | 2,268,811 | $109M | New | Mar 2026 |
| 20 | Two Sigma Investments, Lp | 2,251,525 | $108M | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$22.78B
Enterprise Value
$37.98B
P/E (TTM)
29.83x
Forward P/E
10.82x
PEG Ratio
1.04x
P/B
2.35x
P/S
12.46x
P/FCF
11.90x
EV/EBITDA
23.22x
Shares Out
559.6M
Financials (TTM)
Revenue
$2.38B
Net Income
$770.9M
EBITDA
$1.64B
Free Cash Flow
$2.49B
Op Cash Flow
$2.49B
EPS Basic
$2.33
EPS Diluted
$1.80
EPS Forward
$4.89
Gross Margin
100.0%
Op Margin
65.6%
Net Margin
32.4%
Balance Sheet
Total Assets
$19.62B
Total Liab.
$9.91B
Total Equity
$9.71B
Cash
$637.5M
LT Debt
$8.57B
Book Value/Sh
$22.49
Debt/Equity
1.38x
Current Ratio
0.97
Quick Ratio
0.97
Returns & Growth
ROE
20.4%
ROA
3.9%
ROIC
8.9%
Rev Growth YoY
+5.1%
EPS Growth YoY
+20.7%
Price Returns
2W
+4.4%
1M
+11.3%
3M
+20.7%
6M
+39.3%
12M
+69.6%
Technicals
52W High
$56.50
52W Low
$34.08
50d MA
$51.91
200d MA
$43.26
RSI (14)
35.40
ATR (14)
$1.41
Beta
0.39
Avg Volume
4.1M
Dividends
Div Rate
$0.88
Div Yield
1.8%
Frequency
4
Ex-Div Date
May 15, 2026
Analyst Price Targets
Consensus
$53.75
High
$63.00
Low
$45.00
Median
$53.50
Data updated apr 26, 2026 11:29pm
· Source: financialmodelingprep.com